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Abstract
Introduction: GLUT4 is a representative of the family of integral membrane proteins which facilitate glucose transport across cellular
membranes. In the available literature there is no publication referring to the investigations of glucotransporter expression in pre-diabetic
subjects. However, GLUT4 protein overexpression was shown in leukocytes of diabetic patients. The aim of this study was to compare
GLUT4 quantitative expression in peripheral blood lymphocytes in type 2 diabetes mellitus risk groups to healthy subjects.
Material and methods: The study groups included 15 pre-diabetic subjects and 15 persons with normal glucose tolerance and positive
family history of type 2 diabetes mellitus (first-degree relatives). As a control group, 15 healthy persons with no family history of diabetes
were enrolled. The expression of GLUT4 on the surface of peripheral blood lymphocytes was investigated with the use of indirect immu-
nofluorescence. Quantitative determination of GLUT4 was performed with the use of flow cytometry.
Results: In the control group, GLUT4 expression amounted to 12 ± 1.5% and was significantly lower in relation to both pre-diabetic
subjects (18.2 ± 8.8%; p = 0.008) and the positive family history group (17.9 ± 9%; p = 0.001).
Conclusions: GLUT4 overexpression in subjects with positive family history of type 2 diabetes mellitus suggests that cellular glucose
transport disturbances occur prior to hyperglycaemia. Determination of GLUT4 expression appears to be a possibly useful method of early
detection in individuals at high risk of diabetes. (Pol J Endocrinol 2010; 61 (3): 269–274)
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Streszczenie
Wstęp: Glukotransporter 4 (GLUT4) jest przedstawicielem rodziny integralnych białek błonowych transportujących glukozę do komórek
na drodze dyfuzji ułatwionej. W dostępnym piśmiennictwie stwierdzano zwiększoną ekspresję białka GLUT4 na powierzchni leukocy-
tów osób chorych na cukrzycę; nie ma natomiast publikacji dotyczących badania ekspresji glukotransporterów u osób ze stanem przedcu-
krzycowym. Celem pracy było porównanie ilościowej ekspresji GLUT4 na limfocytach krwi obwodowej u osób należących do grup ryzy-
ka cukrzycy typu 2 oraz u osób zdrowych.
Materiał i metody: Do badania włączono 15 osób ze stanem przedcukrzycowym oraz 15 osób metabolicznie zdrowych z dodatnim wy-
wiadem rodzinnym w kierunku cukrzycy typu 2 (pokrewieństwo pierwszego stopnia). Grupę kontrolną stanowiło 15 osób zdrowych
z negatywnym wywiadem rodzinnym. Do znakowania limfocytów wykazujących ekspresję białka GLUT4 użyto techniki immunofluore-
scencji pośredniej. Ilościowego oznaczenia GLUT4 na komórkach dokonano przy użyciu cytometru przepływowego.
Wyniki: Ekspresja GLUT4 w grupie kontrolnej wynosiła 12 ± 1,5% i była znamiennie niższa od ekspresji GLUT4 w grupie osób ze stanem
przedcukrzycowym (18,2 ± 8,8%, p = 0,008) oraz z dodatnim wywiadem rodzinnym (17,9 ± 9%, p = 0,01).
Wnioski: Zwiększona ekspresja GLUT4 u osób z dodatnim wywiadem rodzinnym w kierunku cukrzycy typu 2 sugeruje istnienie zabu-
rzeń dokomórkowego transportu glukozy w fazie przedhiperglikemicznej. Wydaje się, że oznaczenie ekspresji GLUT4 u osób z grup
zwiększonego ryzyka może być wartościowym testem do wczesnego wykrywania cukrzycy.
(Endokrynol Pol 2010; 61 (3): 269–274)
Słowa kluczowe: cukrzyca typu 2, stan przedcukrzycowy, transport glukozy, GLUT, limfocyty
The study was a part of a project lead under the grant from MNiSW no 2P05B04330.
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Introduction
Glucose is a major energetic substrate for human cells
with lipid cellular membrane impenetrable to monosac-
charides. The cellular glucose transport is possible due
to the special transport system created by two groups
of proteins: glucotransporters (GLUT) and lesser-known
sodium-dependent glucose cotransporters (SGLT). The
presence of these transporters has been observed in
nearly all human cells. While SGLT proteins are in-
volved in the secondary active glucose transport (they
draw the energy from the electrochemical Na+ ion gra-
dient), the cellular glucose transport by means of glu-
cotransporters is based on the principle of facilitated
diffusion, without energy, in accordance with the con-
centration gradient. Glucotransporters are a family of
integral membrane proteins which significantly differ
from each other in kinetic characteristics, substrate spec-
ificity, and tissue expression [1–3]. To date, 14 glu-
cotransporters have been identified, the first of which
was described over 20 years ago. These proteins are
abbreviated as GLUT1–12, HMIT1, and GLUT14. The
genes coding them are described in accordance with
the established nomenclature (HUGO Nomenclature
Committee) as SLC2A1-SLC2A14 [4–6]. Particular iso-
forms differ from each other in the amino-acidic se-
quences, but the general outline of their construction is
similar. About 50% of the protein mass is constituted
by a highly conservative intracellular domain, the seg-
ments of which create 12 a-helices formed into a hy-
drophilic channel allowing the sugar transport to take
place. Other domains are less conservative — extracel-
lular and cytoplasmatic, which contains the N-termi-
nus fragment, C-terminus fragment and the large loop
linking segments 6 and 7. Three classes have been de-
termined within the glucotransporter family. Class I
includes the earliest identified and best known isoforms
— GLUT1–4. GLUT5 belongs in Class II along with
GLUT7, GLUT9, and GLUT11, which are related to it.
Class III gathers proteins characterized by the presence
of the site of glycosylation in loop 9, not 7 as in the case
of two other classes.
Expression of particular GLUT isoforms is specific
for cells and tissues and is not constant but is modified
by hormonal and environmental factors [7–10, 16–20].
In different diseases such as diabetes, tumours, and tis-
sue ischaemia, varied expression of particular glu-
cotransporter isoforms is observed. To date, studies have
shown that glucotransporters 1, 3, and 4 are present on
the surface of leukocytes, and the level of expression of
the genes coding them, and the regulation of this ex-
pression, remains in a close relationship with the func-
tions of particular cells [11–15]. As proven by earlier
studies [13, 15, 21], the lymphocytes constitute an espe-
cially convenient experimental model for the assessment
of cellular glucose transport, due to the ease of acquire-
ment of the study material, which allows invasive pro-
cedures such as muscle or adipose tissue biopsy to be
avoided. Furthermore, contrary to the other white blood
cell populations, they are relatively easy to isolate from
the peripheral blood and have a long in-vitro lifespan.
Aim of the study
The aim of the study was the quantitative comparison
of GLUT4 protein expression — as a main glucose trans-
porter sensitive to insulin — on the surface of periph-
eral blood lymphocytes in a group in pre-diabetic stage
and in a group of metabolically healthy individuals with
positive family history of type 2 diabetes mellitus, as
compared with a group of healthy individuals with
negative family history of type 2 diabetes mellitus.
Material and methods
The study was conducted on a group of 45 individuals
of both genders, aged 35–75 years, who were qualified
appropriately to one of the three equally populated
groups: Individuals with impaired fasting glycaemia
and/or impaired glucose tolerance (pharmacologically
untreated); metabolically healthy individuals with pos-
itive family history of type 2 diabetes mellitus (first-de-
gree relatives); and healthy individuals with negative
family history of type 2 diabetes mellitus (control group)
— selected on the basis of demographic and anthropo-
metric features (Table I). All the participants of the study
were informed about the aim and the course of the ex-
aminations, and were included in the study after they
signed consent forms. The following individuals were
excluded from the study:
— persons with renal failure (creatinine concentration
>  2.5 mg/dl);
— persons with liver impairment (transaminase activity
≥ 3 × upper limit of the norm);
— persons with symptomatic heart failure;
— persons with neoplastic disorders in the course of
last five years;
— persons using diabetogenic medicines (e.g. systemic
corticosteroids, oral contraceptives, thiazide diuretics,
miconazole);
— persons with alcohol or medicine abuse; addicted
to medicines in the course of the last year;
— pregnant women, lactating women.
Patients were qualified to particular groups on the
basis of medical examination, with special focus on med-
ical history (standardized survey examination allowing
the gathering of demographic, environmental, and clin-
ical data) as well as laboratory examinations. The charac-
teristics of examined individuals are given in Table I.
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The following tests were performed in all volunteers:
fasting glycaemia test (enzymatic method), oral glucose
tolerance test (in accordance with WHO), glycated hae-
moglobin HbA1c test (HPLC method), and tests for fast-
ing insulin and fasting C peptide (radio immunological
method).
Additionally, a fasting blood sample (10 ml) was
drawn from all of the participants, from which the lym-
phocytes were isolated in order to mark the quantita-
tive expression of glucotransporters on their surface.
The lymphocyte isolation was performed with the use
of Gradisol L (“Aqua-Medica” Poland) (2800 rpm.,
20 min.). The gathered lymphocytes were rinsed twice
with 0.9% NaCl solution (1800 rpm., 10 min.). After rins-
ing, the lymphocytes were suspended in such a mea-
sured dose of the so-called “transport solution” (Kaliman
et al. 1995) as to ensure that the density was 106 cells/ml
in each trial. The technique of single-colour indirect im-
munofluorescence was employed in the labelling of lym-
phocytes displaying the expression of studied GLUT pro-
teins. To this aim, the monoclonal antibodies (MoAb) anti-
GLUT4 were used along with the unspecific antibody
labelling F(ab’)2 immunoglobulin fragment, linked with
the fluorescein isothiocyanate (FITC). The negative con-
trol was conducted in order to rule out the possibility of
autofluorescence of the cells, and a positive control was
conducted to eliminate the unspecific binding of the
FITC-labelled antibody. Quantitative tests of glucotrans-
porter expression were conducted with the use of the
flow cytometry. The FACS-Calibur type flow cytometer
with CellQuest software (Becton-Dickinson) was used
for the acquisition and analysis of the data.
Statistical analysis
STATISTICA software was used in the analysis of the
data. The acquired data are presented in the form of
mean values and standard deviations. Quantitative
parameters were compared using the t-Student test.
P = 0.05 was assumed as the significance level threshold.
Results
The group of persons in the pre-diabetic stage and the
group of metabolically healthy persons with positive
family history of type 2 diabetes mellitus were charac-
terized by higher BMI and systolic and diastolic blood
pressure values in comparison to the control healthy
subjects. The differences between the group of meta-
bolically healthy persons with positive family history
of type 2 diabetes and the control group were not sta-
tistically significant (Table I).
Mean values of the assessed biochemical parame-
ters as compared with the control group (Table II).
In the group of persons in the pre-diabetic stage a sig-
nificantly higher (as compared with the control group)
mean value of fasting glycaemia (6.05 mmol/L v.
5.13 mmol/L, p < 0.0005) and HbA1c (5.95% v. 4.9%, p =
= 0.0001) was observed along with significantly higher
indices of insulin resistance. In these groups, the fast-
ing insulin level was appropriately 12.74 mU/L v.
7.92 mU/L (p < 0.05). The differences in the area of the
HOMA-IR index were similar (3.38 v. 1.84, p < 0.01). In
the group of metabolically healthy persons with posi-
tive family history of type 2 diabetes mellitus, the mean
values of examined biochemical parameters were low-
er than in the group of persons with impaired fasting
glycaemia (IFG) and/or impaired glucose tolerance
(IGT), and higher than in the control group. The ob-
served differences were not statistically significant, apart
from the HbA1c, in relation to the control group.
The study showed that mean expression of GLUT4
protein in the group of metabolically healthy persons
Table I. Characteristics of the examined groups
Tabela I. Charakterystyka badanych grup
Parameter Control group Possitive family history IFG/IGT
Number of participants 15 15 15
SEX (M/W) 8/7 5/10 5/10
AGE (years) 48.6 ± 11.4 46.6 ± 8.78 46.33 ± 5.58
SI SI
BMI [kg/m2] 27.68 ± 2.44 28.13 ± 3.17 30.55 ± 4.68
SI p < 0.05
SBP [mm Hg] 127.3 ± 13.3 132.0 ± 19.53 144.0 ± 10.56
SI p < 0.001
DBP [mm Hg] 77.0 ± 9.2 84.33 ± 16.68 95.33 ± 7.9
SI p < 0.0001
BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; IFG — impared fasting glycaemia; IGT — impared glucose
tolerance; SI — statistically insignificant
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with positive family history of type 2 diabetes mellitus
was 17.9% and was very close to the mean expression
of this protein in the group in the pre-diabetic stage, in
which it was 18.2%. These values were clearly higher
than those observed in the control group (12%), and
the acquired differences displayed statistical significance
(Fig. 1).
Discussion
The growing incidence of diabetes mellitus constitutes
a major socio-economic problem. The early identifica-
tion of persons from the groups of increased risk for
this disease allowing the introduction of preventive
countermeasures, therefore, gains importance. It has
been proven that the prevalence of abnormal glucose
tolerance in subjects with at least one of the risk factors
for type 2 diabetes mellitus is near 40% [22]. Moreover,
it is well established that diabetes mellitus and IFG/IGT
are observed more frequently in several other endocrin-
opathies (e.g. acromegaly) than in the general popula-
tion [23]. Conventional biochemical methods (oral glu-
cose tolerance test [OGTT], fasting plasma glycaemia
[FPG]) allow the identification of persons in the pre-
diabetic stage, i.e. with IFG and/or IGT. It has been prov-
en that nondiabetic hyperglycaemia is related not only
to a higher risk of the development of diabetes, but also
to cardiovascular diseases [24]; therefore, the fasting
glycaemia test and OGTT are insufficient for early de-
tection of such persons. Furthermore, the OGTT is char-
acterized by low repeatability and demands the use of
advanced standardization, and its employment in the
area of active diagnosis of diabetes is connected with
organizational and financial difficulties [25]. In spite of
the extreme complexity of the pathophysiological mech-
anisms that are the basis for the occurrence of diabetes,
the only test used for the diagnosis of this disease is
glucose concentration measurement. Glycaemia tests
are insufficient for the appropriate earlier identification
of persons at risk for the development of diabetes. Many
studies have focused on investigations of the useful-
ness of other parameters in the risk assessment of dia-
betes development. It has been revealed that the pres-
ence of higher fasting levels of C-peptide in first degree
relatives of the autoimmunological diabetic patients
with no clinical symptoms of type 1 diabetes could be
a prognostic factor to retard the clinical symptoms of the
disease [26]. Numerous growth factors have been re-
ported to be involved in the pathogenesis of diabetes
mellitus and its long-term complications. It has been
proven that the blood concentration of hepatocyte
growth factor (HCG) is increased in patients with type 1
diabetes with proliferative retinopathy, and concentra-
tions increase with the progression of retinopathy [27].
Table II. Comparison of the results of laboratory examinations
Tabela II. Porównanie wyników badań laboratoryjnych
Parameter Control group Positive family history IFG/IGT
Fasting glycaemia [mmol/L] 5.13 ±0.66 5.25 ±0.37 6.05 ±0.53
SI p < 0.0005
HbA1c (%) 4.9 ±0.6 5.77 ±0.56 5.95 ±0.61
p < 0.0005 p = 0.0001
Fasting insulin [mU/L] 7.92 ±3.76 9.04 ±1.52 12.74 ±7.65
SI p < 0.05
HOMA-IR 1.84 ±1.01 2.13 ±1.52 3.38 ±1.9
SI p < 0.01
IFG — impared fasting glycaemia; IGT — impared glucose tolerance; SI — statistically insignificant
Figure 1. Comparison of the quantitative expression of GLUT4
on the surface of peripheral blood lymphocytes in the control group,
the group of metabolically healthy persons with positive family
history of type 2 diabetes mellitus, and the group of persons in the
pre-diabetic state
Rycina 1. Porównanie ilościowej ekspresji GLUT4 na powierzchni
limfocytów krwi obwodowej w grupie kontrolnej, grupie osób
metabolicznie zdrowych z dodatnim wywiadem rodzinnym
w kierunku cukrzycy typu 2 oraz osób ze stanem przedcukrzycowym
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A major role in the pathogenesis of diabetes is played
by cellular glucose transport disorders. It seems that
their diagnosis in the prehyperglycaemic phase and the
introduction of appropriate preventive measures could
yield notable clinical and economic benefits. Impaired
cellular glucose transport is mirrored by the altered ex-
pression of glucotransporters on the cellular surface. It
has been proven that both in the case of chronic hyperg-
lycaemia and in circumstances of lengthy hypoglycaemia,
an increased expression of glucotransporters occurs on the
surface of white blood cells. It was shown that hypogly-
caemia induces the significant growth of GLUT3 protein
expression on the surface of monocytes, and GLUT4 and
GLUT3 on the surface of granulocytes [10]. In the men-
tioned study, the presence of glucotransporters on the
surface of lymphocytes was not observed, which is con-
tradictory to the results of later studies [13, 14, 28].
To date, the focus of studies has been on the exam-
ination of glucotransporters in patients with diabetes
and the growth of their expression on the cellular sur-
face, as compared with individuals with normal glycae-
mia [13, 15, 28, 29]. This phenomenon probably consti-
tutes the adaptive mechanism allowing the adjustment
of the immunocompetent cells to the altered metabolic
circumstances. The complex system of cellular glucose
transport is equipped with an autoregulatory mecha-
nism, and the impairment of this mechanism leads to
disorders of the function of particular populations of leu-
kocytes, which can explain the more frequent incidence
of tumours and immunity disorders in patients with di-
abetes compared with the general population [30–34].
Even though many studies have been concerned
with the notion of cellular glucose transport in individ-
uals with diabetes, in the available literature there are
no publications concerning examinations of the expres-
sion of glucotransporters in the group of pre-diabetic
individuals and the group of metabolically healthy per-
sons with positive family history of diabetes mellitus.
In our study, a significantly increased (as compared
with the control group) expression of GLUT4 protein
on the surface of peripheral blood lymphocytes was
observed in both the persons with IFG and/or IGT and
in the metabolically healthy persons with positive fam-
ily history of type 2 diabetes mellitus. This indicates that
glucose metabolism disorders, including cellular glucose
transport disturbances, occur in the early phase of dia-
betes development before the biochemical indices of this
disease can be observed.
Conclusions
1. The increased expression of GLUT4 transport pro-
tein on the surface of peripheral blood lymphocytes
in persons with proper glycaemia and positive family
history of type 2 diabetes mellitus points to the ex-
istence of cellular glucose transport disorders already
in the prehyperglycaemic phase.
2. Quantitative labelling of GLUT4, and probably of
other proteins belonging in the GLUT family, gives
hope for the development of diagnostic methods for
the purpose of practical prevention of diabetes mel-
litus.
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